Aptevo Secures $60M Equity Line, Reports $14.5M Cash to Fund Pipeline
APVO sits 25% above its 52-week low of $3.8 on light trading volume (0.3× avg).
Summary
Aptevo Therapeutics announced a Q1 2026 operational update, revealing $14.5 million in cash and cash equivalents as of March 31, 2026, and a newly secured $60 million standby equity purchase agreement. This financing is critical for the company, which previously disclosed substantial doubt about its ability to continue as a going concern in its last 10-K. The $60 million equity line, while highly dilutive given the company's small market capitalization, provides a vital funding pathway to advance its pipeline. This capital infusion significantly improves the company's financial flexibility and ability to capitalize on its recent positive Phase 1b clinical results for mipletamig, mitigating immediate liquidity concerns. Traders will be watching for the utilization of this equity line and further clinical milestones.
At the time of this announcement, APVO was trading at $4.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $3.80 to $258.01. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.